Pfizer and BioNTech on Tuesday submitted an application to the Food and Drug Administration (FDA) requesting authorization to administer a booster dose of their COVID-19 vaccine to children aged 5-11.
In an announcement quoted by The Hill, Pfizer cited data from a Phase 2/3 trial, which it says indicated a “strong immune response” in the younger age group after a booster dose was administered six months after primary immunization with its COVID-19 vaccine.
Read more